Zanubrutinib for treating Waldenstrom's macroglobulinaemia (WM)
Zanubrutinib is a next-generation Bruton tyrosine kinase (BTK) inhibitors that was developed to achieve BTK inhibiting efficacy while reducing the off-target adverse events documented with ibrutinib therapy
NICE state:
Reference:
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page